Plavix news from FiercePharma
News
Rumor mill: BMS positioning itself for sale
Speculation that Bristol-Myers Squibb might be a takeover target -- that's old news. Informed speculation based on certain strategic moves BMS has made recently -- worth passing on. Tim Anderson, the Read more...
Setback for Lilly, gain for Plavix?
SPOTLIGHT: Setback for Lilly, gain for Plavix?When FDA delayed its decision on Eli Lilly's clot-buster prasugrel, a.k.a. Effient, it sliced at least three months off the time Lilly might have to win Read more...
Plavix copycat pops up in Europe
Call it generic Whac-a-Mole. Sanofi-Aventis and Bristol-Myers Squibb have bludgeoned copycat Plavix in the U.S., but competition is now popping up in Europe. Swiss drugmaker Schweizerhall Holding Read more...
As former exec indicted, BMS posts growth
A triad of Bristol-Myers Squibb news today, some good, some not-so-good. First, let's get the earnings out of the way: The company reported a decline in earnings on restructuring charges, but Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
Dems back compulsory licensing
Now Rep. Henry Waxman and 26 of his Congressional Read more...
Analysts put BMS on takeover menu
Analysts are salivating over Bristol-Myers Squibb. Healthy earnings and sales growth, coupled with a stock price down by about a third since last July, makes the drugmaker "an attractive takeover Read more...
Thai official backs off licensing fight
The brief ray of patent-respecting sunlight from Thailand has gone behind the old Read more...
Fearing sanction, Thais may pay for drugs
Thailand may be running scared. Remember, the new health minister promised last week to review the country's compulsory licenses--which essentially break patent rules so that cheap meds can be had Read more...
Earnings from Schering, Sanofi, Teva
It's an earnings kind of day today, with two of the brand-name biggies reporting, plus the leading generics maker. Here are the results:Schering-Plough reported a $3.4 billion loss for the fourth Read more...
Get more Plavix coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends